Ohio doctor loses federal drug authority after license lapse
Published Date: 10/20/2026
Notice
Summary
Dr. Jan Pijanowski from Ohio lost his DEA registration because his medical license expired and he didn’t respond to the DEA’s notice. This means he can no longer prescribe or handle controlled substances, effective immediately. If you’re a patient or pharmacy, this change is official as of October 2026 and affects any prescriptions tied to him.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Pijanowski
The Drug Enforcement Administration revoked Jan Pijanowski, M.D.'s DEA Certificate of Registration No. FP3656153. The Order states he is not licensed to practice medicine in Ohio (his Ohio license expired on July 14, 2025) and the revocation is effective November 19, 2026.
Pending DEA Applications Denied in Ohio
The Order denies any pending applications of Jan Pijanowski, M.D., to renew or modify Certificate of Registration No. FP3656153 and denies any other pending application by him for additional DEA registration in Ohio. This denial is part of the Order effective November 19, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-21413, Jefferson Burroughs, M.D.; Decision and Order
Dr. Jefferson Burroughs from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of July 31, 2026. This means Dr. Burroughs can’t legally prescribe or manage controlled drugs anymore, affecting his medical practice and patients.
2026-21410, Youmna Abdulhadi, M.D.; Decision and Order
Dr. Youmna Abdulhadi from California lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration as of June 30, 2026. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
Previous / Next Documents
Previous: 2026-21413, Jefferson Burroughs, M.D.; Decision and Order
Dr. Jefferson Burroughs from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of July 31, 2026. This means Dr. Burroughs can’t legally prescribe or manage controlled drugs anymore, affecting his medical practice and patients.
Next: 2026-21415, Peter Michael Wills, D.D.S.; Decision and Order
Dr. Peter Michael Wills from Ohio lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of May 31, 2026. This means he can’t legally prescribe or manage controlled drugs anymore, affecting his dental practice and any related income.